MRK vs PATH · P/E 33, rev $65.01B vs P/E 19, rev $1.61B
Merck & Company Inc (MRK) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported MRK revenue for 2025-12-31 was $65.01B. Net income was $18.25B. Revenue was up 1.3% from 2024-12-31 to 2025-12-31. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the MRK and PATH stock pages for the full models.
Not investment advice.